Loading
A phase 2 trial of Adagrasib in metastatic cancer, run by Mirati Therapeutics Inc., active and no longer recruiting.
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) is a phase 2 interventional study registered as NCT05853575 by Mirati Therapeutics Inc., with 200 participants planned, started 2024-02-01 and due to reach its primary completion in 2026-10-30. Interventions recorded: Adagrasib. Conditions listed: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung. No results are recorded here; the registry entry is the source.
Shares Adagrasib, KRAS & RAS inhibitors, Bristol Myers Squibb.
Shares Adagrasib, KRAS & RAS inhibitors, Bristol Myers Squibb, Metastatic cancer (cancer that has spread).
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread).
Shares Adagrasib, KRAS & RAS inhibitors, Bristol Myers Squibb.
Shares Adagrasib, KRAS & RAS inhibitors, Bristol Myers Squibb.
Shares Adagrasib, KRAS & RAS inhibitors, Bristol Myers Squibb.
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread).
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread).